Actinogen Medical Limited (ASX:ACW)

Market Cap	65.78M
Revenue (ttm)	9.02M
Net Income (ttm)	-9.66M
Shares Out	3.13B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,784,197
Average Volume	15,422,318
Open	0.0200
Previous Close	0.0200
Day's Range	0.0200 - 0.0210
52-Week Range	0.0190 - 0.0990
Beta	1.09
RSI	35.20
Earnings Date	May 23, 2025

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11β-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medica...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 6
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACW

Financial Performance

In 2024, Actinogen Medical's revenue was 9.93 million, an increase of 103.18% compared to the previous year's 4.89 million. Losses were -13.04 million, 21.3% more than in 2023.